A study involving six international amyloid centres and including 118 patients with ATTR-CM (either genetic or wild type) [188] demonstrated that almost one-third of patients without HF symptoms at initial evaluation developed HF after a median follow-up period of 3.7 years. This evidence concerns the gene TTR and hydrops fetalis.